FORT LEE, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical...
Oslo, Norway, 18 October 2022 Vistin Pharma ASA will release its third quarter and YTD 2022 results on Wednesday 26th of...
Helsinn publishes new data evaluating chlormethine gel’s mode of action in Dermatology and Therapy Lugano, Switzerland, October 18, 2022 -...
Immix Biopharma, Inc. (NASDAQ:IMMX) ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma...
Adaptive and efficient trial design may allow for expedited development timeline while maintaining scientific rigorWALTHAM, Mass., Oct. 18, 2022 (GLOBE...
PetVivo Holdings, Inc. John LaiMINNEAPOLIS, Oct. 18, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an...
SAINT LAURENT, Quebec, Oct. 18, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical...
FLORHAM PARK, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing...
CHICAGO and FORT WORTH, Texas, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing...
Aligos’ pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023SOUTH SAN FRANCISCO, Calif., Oct. 18,...
Avicenna Academy Avicenna AcademyThe education portal provides modules, case studies and other resources related to medical cannabis for Health Care...
Chiesi USA recognized for its dedication to ensuring that employee voices are heard and valuedCARY, N.C., Oct. 17, 2022 (GLOBE...
Phase 1 Study (with 58 healthy volunteers) of STI-1558 was completed in Australia with 300 mg, 600 mg, 1,200 mg...
New co-pay program will increase access to the Monarch eTNS® System for commercially insured children ages 7 – 12 with...
MORRISVILLE, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today...
Biomea Fusion announces FDA clearance of Investigational New Drug (IND) application for covalent menin inhibitor BMF-219 in KRAS solid tumors.Biomea...
HOUSTON, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients...
WOBURN, Mass., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the...
DURHAM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN) and EPI Health, a...
Updated interim data to be presented from the IgA nephropathy (IgAN) patient cohort of the atrasentan phase 2 AFFINITY basket...